Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I-II Trial of the Anti CD74 Monoclonal Antibody-Milatuzumab as a Single Agent in Refractory Chronic Lymphocytic Leukemia

NCT00868478 is registered in ClinicalTrials.gov with Kaplan Medical Center as lead sponsor.

NCT NCT00868478
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00868478 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I-II Trial of the Anti CD74 Monoclonal Antibody-Milatuzumab as a Single Agent in Refractory Chronic Lymphocytic Leukemia
Lead sponsor
Kaplan Medical Center
Phase
Phase 1/2
Overall status
Unknown status
Start date
April 30, 2009
Completion date
April 30, 2012
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia